J&J CFO Caruso on 2Q Results, Product Pipeline, M&A

The video discusses Johnson & Johnson's strong Q2 results, highlighting growth in pharmaceuticals, consumer products, and medical devices. Key topics include the pharmaceutical pipeline, competition, the strategic acquisition of Vogue, and the impact of Brexit. The restructuring of the medical devices segment is also covered, along with the company's approach to mergers and acquisitions and financial strategies in light of currency fluctuations.

What was a key factor in Johnson & Johnson's strong second-quarter results?

• Decline in competition

• Improvement across all business sectors

• Increase in marketing expenses

• Reduction in operational costs

How many new pharmaceutical products does Johnson & Johnson plan to file with regulatory agencies by 2019?

• 20

• 15

• 10

• 5

What is the mechanism of action for DARZALEX?

• Anti-inflammatory agent

• CD 38 antibody

• Protein inhibitor

• Gene therapy

Why was the acquisition of Vogue significant for Johnson & Johnson?

• It reduced their operational costs

• It strengthened their position in the hair care market

• It expanded their pharmaceutical portfolio

• It increased their European market share

What percentage of Johnson & Johnson's revenue comes from Europe?

• 10%

• 15%

• 20%

• 25%

What was a result of the restructuring in Johnson & Johnson's medical devices sector?

• Increased operational costs

• Accelerated growth and innovation

• Decreased innovation pace

• Reduced market presence

What is Johnson & Johnson's primary foreign exchange exposure?

• Euro

• Japanese Yen

• Canadian Dollar

• British Pound